Home Page

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Epigenetics Market by Offering (Kits, Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology) End User (Pharma, Academics, Hospitals) - Global Forecast to 2030" report has been added to  ResearchAndMarkets.com's offering.

The epigenetics market is expected to reach $5.47 billion by 2030, at a CAGR of 15.7% from 2023 to 2030.



The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.



The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.

Asia-Pacific is slated to register the highest CAGR during the forecast period. The market growth in this region is attributed to government initiatives for genetic diseases, growing cancer incidence, rising geriatric population, rapid rise in the prevalence of chronic diseases, rising R&D spending, and increasing healthcare expenditure.



Based on offering, the epigenetics market is segmented into kits & reagents, instruments and accessories, software and services.

The kits & reagents segment is expected to grow at the fastest CAGR during the forecast period. The frequent and repetitive use of kits and reagents and the growing prevalence of chronic diseases are the major factors responsible for segment growth.



Based on method, the epigenetics market is segmented into DNA methylation, histone modification, RNA modification, polymerase chain reaction (PCR), chromatin analysis, sonication, and other methods.

In 2023, the DNA methylation segment is expected to account for the largest share of the market. DNA methylation is an epigenetic mechanism that involves transferring a methyl group onto the C5 position of cytosine to form 5-methylcytosine. This process regulates gene expression by promoting or inhibiting the binding of transcription factors to DNA. Thus, it is useful in studying epigenetic changes in an organism. The increasing prevalence of cancer, technological advancements in PCR and sequencing, and the high focus on reducing costs associated with lengthy research and product approval processes support the segment's large share.



Based on application, the epigenetics market is segmented into oncology and non-oncology.

In 2023, the oncology segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high burden of cancer, the high focus on R&D regarding cancer, and the growing demand for precision oncology.



Based on end user, the epigenetics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and hospitals & diagnostic laboratories.

In 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. The segment's large share is attributed to the rising demand for research-related products, the increasing incidence of chronic diseases, pharmaceutical & biotechnology companies' rising R&D expenditures, technological advancements in epigenetics, and the introduction of new epigenetics products for chronic and rare diseases.

Company Profiles (Business Overview, Financial Overview, Product Portfolio SWOT Analysis, and Strategic Developments)

• Thermo Fisher Scientific Inc. (U.S.)
• Merck KGaA (Germany)
• Illumina Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• New England Biolabs (U.S.)
• Epigentek Group Inc. (U.S.)
• Pacific Biosciences of California Inc. (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• PerkinElmer Inc. (U.S.)
• 10X Genomics Inc. (U.S.)
• Active Motif (U.S.)
• Zymo Research Corporation (U.S.).

Competitive Analysis

• Key Growth Strategies
• Competitive Benchmarking
• Competitive Dashboard
• Industry Leaders
• Market Differentiators
• Vanguards
• Emerging Companies
• Market Share Analysis (2022)
  • Merck KGaA (Germany)
  • 10X Genomics, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Illumina, Inc. (U.S.)
  • QIAGEN N.V. (Netherlands)

Scope of the Report

Epigenetics Market Assessment, by Offering

• Kits & Reagents
• Kits & Assays
• Antibodies
• Proteins & Enzymes
• Other Reagents

(Other reagents include buffers, controls, beads, histones, master mixes, and nuclease-free water)

• Services
• Software

Epigenetics Market Assessment, by Method

• DNA Methylation
• Bisulfite Conversion
• High-resolution Melt (HRM) Analysis
• Immunoprecipitation
• Other DNA Methylation Methods

(Other DNA methylation methods include activity/inhibition assays, methylated DNA quantification, and methylated DNA amplification)

• Histone Modification
• RNA Modification
• Polymerase Chain Reaction
• Chromatin Analysis
• Sonication
• Other Methods

(Other methods include in vitro DNA-protein interactions, DNA demethylation, and miRNA analysis)



Epigenetics Market Assessment, by Application

• Oncology
• Non-oncology

Epigenetics Market Assessment, by End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Diagnostic Laboratories

Epigenetics Market Assessment, by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• Latin America
• Middle East & Africa

For more information about this report visit https://www.researchandmarkets.com/r/agpuv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

 

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

 

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/epigenetics-market-research-report-2023-2030-dna-methylation-and-oncology-applications-at-the-forefront-of-advancements-302077372.html

SOURCE Research and Markets